These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 404579)

  • 21. Risk factors for motor response complications in L-dopa-treated parkinsonian patients.
    Peppe A; Dambrosia JM; Chase TN
    Adv Neurol; 1993; 60():698-702. PubMed ID: 8420213
    [No Abstract]   [Full Text] [Related]  

  • 22. Madopar HBS in nocturnal symptoms of Parkinson's disease.
    Jansen EN; Meerwaldtt JD
    Adv Neurol; 1990; 53():527-31. PubMed ID: 2239493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors that influence the occurrence of response variations in Parkinson's disease.
    de Jong GJ; Meerwaldt JD; Schmitz PI
    Ann Neurol; 1987 Jul; 22(1):4-7. PubMed ID: 3631919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 26. [L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():93. PubMed ID: 11434272
    [No Abstract]   [Full Text] [Related]  

  • 27. Amantadine and a fixed combination of carbidopa and levodopa in parkinsonism: a preliminary report.
    Savery F
    Curr Ther Res Clin Exp; 1976 Mar; 19(3):337-8. PubMed ID: 817863
    [No Abstract]   [Full Text] [Related]  

  • 28. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lisuride in the combination treatment of Parkinson disease].
    Jellinger K
    Wien Med Wochenschr; 1987 Apr; 137(7-8):155-9. PubMed ID: 3111099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Considerations in the management of parkinsonism.
    Fahn S; Calne DB
    Neurology; 1978 Jan; 28(1):5-7. PubMed ID: 339124
    [No Abstract]   [Full Text] [Related]  

  • 31. Drugs for parkinsonism.
    Med Lett Drugs Ther; 1986 Jun; 28(716):62-4. PubMed ID: 3713639
    [No Abstract]   [Full Text] [Related]  

  • 32. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
    Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
    Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome].
    Binder H; Gerstenbrand F; Grünberger J; Gründig E; Schubert H
    Nervenarzt; 1976 Nov; 47(11):656-60. PubMed ID: 826840
    [No Abstract]   [Full Text] [Related]  

  • 34. [CB 154 in the treatment of parkinson's disease--results of the association with L-DOPA + DDI (author's transl)].
    Meco G; Casacchia M; Zamponi A; Agnoli A
    Schweiz Rundsch Med Prax; 1976 May; 65(18):557-9. PubMed ID: 989900
    [No Abstract]   [Full Text] [Related]  

  • 35. [Dopa-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated hemiparkinsonian monkeys].
    Chen S
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1992 Feb; 25(1):50-2, 64. PubMed ID: 1591961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Improper treatment of patients with parkinsonism due to drug use].
    Meerwaldt JD; Staal A
    Ned Tijdschr Geneeskd; 1982 Jul; 126(28):1257-9. PubMed ID: 7133158
    [No Abstract]   [Full Text] [Related]  

  • 37. Carbidopa/levodopa therapy of coexistent drug-induced parkinsonism and tardive dyskinesia.
    Shoulson I
    Adv Neurol; 1983; 37():259-66. PubMed ID: 6134445
    [No Abstract]   [Full Text] [Related]  

  • 38. [Treatment of Parkinson's syndrome with L-dopa and L-carbidopa (author's transl)].
    Hanzal F
    MMW Munch Med Wochenschr; 1976 May; 118(20):653-6. PubMed ID: 818540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients.
    Manson AJ; Turner K; Lees AJ
    Mov Disord; 2002 Nov; 17(6):1235-41. PubMed ID: 12465062
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The treatment of parkinsonism.
    Godwin-Austen R
    Practitioner; 1975 Oct; 215(1288):445-51. PubMed ID: 1202468
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.